The respondent's prescribing
(6) On 16 August 2018 the respondent took a history of Patient A having "pain in L lower back". On 12 September 2018, the respondent prescribed Oxycodone + Naloxone 10mg/5mg at a dosage rate of one tablet twice a day. The medical records for this day record "low back pains" and no examination notes other than "pulse 60, temperature 37, urinalysis blood trace". The reason for the visit was recorded as "cystitis". There is no record of the respondent having conducted an appropriate assessment of Patient A before prescribing narcotics. The respondent was also required to perform a pain inventory and opioid risk assessment and arrange an agreement for an opioid trial with documentation of specific goals (National Prescribing Service; Medicine Today, "Conventional and atypical opioids" (2018)). The RACGP Guidelines on prescribing drugs of dependence were not followed. Further, the initial treatment for back pain is not pharmaceutical; and Panadeine Forte, which contains the opioid codeine, had already been prescribed on 16 August 2018.:
Finding: This conduct is significantly below the standard reasonably expected of a practitioner of similar training or experience, and invites strong criticism.
(7) On 15 October 2018 the respondent prescribed Oxycodone + Naloxone 10mg/5mg for Patient A. The records for the consultation of that day note: "script only". There is no record of required assessments or notes on effectiveness or any side-effects after the one-month treatment. This conduct is significantly below the standard reasonably expected of a practitioner with similar training or experience and invites strong criticism.
Finding: The Tribunal considers that the conduct of the respondent is below the standard reasonably expected, but not that it is significantly below such standard. The Tribunal does not agree that strong criticism follows.
(8) The respondent continued Patient A's regime of Oxycodone + Naloxone on 18 October 2018, having observed that she, as recorded in the clinical notes, was "depressed… not suicidal… not eating well, sleeps four hours max a day". The outcome tool used as part of the assessment, K 10, produced a result of 41, being significantly high. Common side effects (1-10% of patients) of Oxycodone + Naloxone 10mg/5g include insomnia and uncommon side effects (0.1-1% of patients) include anxiety, confused state, depression, nervousness and restlessness. The respondent made no notes of any triggers identified for depression; no record of consideration of the potential contribution of medication; no record of back pain being reviewed on history or examination, or whether any goals had been achieved after just over one month of opioid prescribing. The transcript of the interview conducted by the applicant on 16 August 2019 (at pp 13-18) records questions were asked concerning the mental health assessment on 18 October 2018. The respondent stated that Patient A had "acute mania" but did not provide details of clinical signs or symptoms associated with the true psychiatric definition of this condition. The respondent admitted that he did not record much information, but rather noted "depressed" because "that's what she mentioned to me".
Finding: Such conduct fell significantly below the standard reasonably expected of a practitioner with similar training or experience and invites strong criticism.
(9) On 18 October 2018 the respondent prescribed Seroquel, indicated for treatment of acute mania associated with bipolar disorder, and Oxycodone + Naloxone for Patient A. The records do not record "acute mania" but rather "depression". There is no record of consideration being given to whether the opioids were the cause of Patient A's mental state. Before commencing treatment with an anti-psychotic, physical examination is required as well as baseline blood tests and ECG. Blood tests were performed on 9 May 2018, but since this consultation was an acute presentation, investigations were necessary. Any history of alcohol or drug use is important to elicit before commencement of Seroquel due to the risk of misuse and abuse. Also, suicide risk is potentially increased in depressed patients. There is no record of such factors being taken into consideration, or of the patient being advised about risks.
Finding: This conduct is significantly below the standard reasonably expected of a practitioner with similar training or experience and invites strong criticism.
(10) Between 15 October 2018 and 21 November 2018 the respondent prescribed Oxycodone + Naloxone for Patient A on three occasions. No record was maintained of an appropriate assessment of the patient before commencing narcotics, when a comprehensive assessment including a full socio-psycho-biomedical assessment was required. Inadequate history or examination findings are recorded. A spinal x-ray was performed on 16 August 2018 which was essentially normal and the source of the pain had not been appropriately identified. There is no diagnosis recorded on any occasion. Review on a one to two weekly basis is advised with initial treatment and at each review there needs to be evaluation and recording of results of pain inventory and assessment of analgesia, activity, adverse effects, affect and any aberrant behaviours. There is no record in the three consultations on 15 October 2018, 11 November 2018 and 21 November 2018 of this being done, despite prescriptions for the opiates being given.
Finding: Such conduct is significantly below the standard reasonably expected of a practitioner with similar training or experience and invites strong criticism.
(11) On 21 November 2018 the respondent concurrently prescribed Olanzapine with Oxycodone + Naloxone for Patient A. Whilst there is no specific drug interaction of these drugs, there is no record of consideration at this consultation of whether the patient's mental state was due to the use of Oxycodone + Naloxone, even though the medical record states: "imagining things… and hearing things + wt loss 10kg". There is no record of any examination and no weight recorded. Seroquel 25mg was prescribed on 18 October 2018: there is nothing in the file to indicate compliance, efficacy or side effects. The dose was sub-therapeutic for treatment of true bipolar disorder, and there is nothing in the medical records to explain the change to another atypical anti-psychotic. This conduct is significantly below the standard reasonably expected of a practitioner with similar training or experience and invites strong criticism.
(12) The patient allegedly queried whether Oxycodone + Naloxone might be causing Patient A's depression. On the assumption that she did, the respondent should have been alerted to the possibility of adverse effects and on this basis the conduct of the respondent in allegedly ignoring such question establishes that his conduct fell significantly below the standard reasonably expected and invites strong criticism.